AOD-9604 Compounding Pharmacy: 503A vs 503B, What You Need to Know Before You Buy

Print or save as PDF

See the public record for AOD-9604

What the two compounding pathways mean

Under the federal compounding law, compounded human drug products are exempt from the Act's provisions on premarket approval, current good manufacturing practice and adequate-directions labeling only if stated conditions are met. One of those conditions is compounding on receipt of a valid patient-specific prescription [9]. The Drug Quality and Security Act of 2013 added a second, voluntary category of compounders, outsourcing facilities. They are subject to CGMP, may distribute compounded drugs without a prescription for an identified patient (provider office stock, for example), are inspected by FDA on a risk-based schedule, and must report adverse events [9].

For AOD-9604, the practical question is whether either type of operation has a listed route to bulk AOD-9604.

Can a state-licensed compounding pharmacy prepare AOD-9604?

State-licensed physicians and pharmacists compounding under federal law may use bulk drug substances only if they comply with an applicable USP or NF monograph, are components of FDA-approved drug products, or appear on FDA's bulks list for state-licensed pharmacies [6]. AOD-9604 is not an FDA-approved drug [1][2]. It appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026 [3]. The category 1 policy, under which the agency generally does not intend to act against compounders that meet the stated conditions, does not cover it [6].

Where it does appear is FDA's page on bulk substances that may present significant safety risks, in the table of substances previously in category 2 that their nominators withdrew (content dated April 22, 2026) [5]. The listed concerns are specific. Compounded drugs containing AOD-9604 may pose significant immunogenicity risk for certain routes of administration, through peptide impurities and characterization problems. FDA has identified no, or only limited, safety information. And FDA states that it has identified serious adverse events that may be associated with AOD-9604, though causality is not clear [5]. The agency gives no further detail on those events. Removal from category 2 followed the nominator's withdrawal and was not a finding that the substance is safe [5].

Can an outsourcing facility prepare AOD-9604?

AOD-9604 is not on FDA's list for outsourcing facilities, updated March 21, 2025 [4]. Compounded drugs are not FDA-approved; FDA does not review their safety, effectiveness or quality before marketing [9]. An outsourcing facility works inside CGMP and risk-based FDA inspection [9].

Did the 2026 federal peptide actions cover AOD-9604?

HHS's draft enforcement-discretion policy for compounded peptides, filed October 28, 2026 as Federal Register document 2026-22192, names six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 [7][10]. AOD-9604 is not one of them [7]. Nor was it on the agenda of FDA's Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026, which took up BPC-157, KPV, TB-500, MOTs-C, emideltide, Semax and epitalon [11]. None of those actions mention AOD-9604 [7][11].

The GRAS claim, checked

FDA's GRAS Notice Inventory contains no AOD-9604 entry. An inventory search on October 29, 2026 for AOD9604, AOD, growth hormone and peptide returned no records, so there is no FDA no-questions letter for it [12]. GRAS is a food-ingredient concept and would not make an injectable lawful as a drug [12].

What human data exist

Start with the molecule. AOD-9604 is human growth hormone residues 177 to 191 with an extra tyrosine at the N-terminus, 16 amino acids in all, which is why it is also called hGH fragment 176-191 [13]. It is not full-length growth hormone, and preclinical work found no growth-hormone-receptor binding [2][13].

The main human test of it was oral, as an anti-obesity drug candidate. A 2026 review reports a 24-week study with 534 people enrolled and 502 randomized that failed to show a significant benefit on the primary weight-loss endpoint. The review notes that the conclusion rests on sponsor-reported phase 2 results rather than peer-reviewed randomized trials, and that robust human data for visceral-fat reduction or other metabolic benefit are lacking [2]. There is no approved dose, and that trial tested an oral candidate, not an injected product [2].

The fat-loss signal comes from rodents. In obese Zucker rats, oral AOD9604 at 500 microgram/kg/day for 19 days reduced weight gain to 15.8 g against 35.6 g in controls, with higher fat-tissue lipolytic activity and no adverse effect on insulin sensitivity by euglycemic clamp [14]. In obese mice, 14 days of intraperitoneal hGH or AOD9604 reduced body weight and fat and raised beta-3 adrenergic receptor RNA; the long-term effect did not appear in mice lacking that receptor [15]. Claims about cartilage or joint repair rest on a single rabbit knee osteoarthritis study of intra-articular AOD9604 [16]; there is no convincing human osteoarthritis trial [2].

What is actually circulating

AOD-9604 turns up outside pharmacies. Belgian authorities identified it in unknown pharmaceutical preparations they seized, and US investigators reported it in confiscated vials [17][13]. A 2026 review of unapproved peptides used in sports medicine noted that many show favorable results in animals while rigorous human safety data are scarce and serious harm is possible [18].

AOD-9604 is also named on WADA's Prohibited List at S2.2.3 as a growth hormone fragment, prohibited at all times in and out of competition, on both the 2026 List and the 2027 tracked-changes version [8][19]. Validated urine detection methods exist for the peptide and its stable metabolite [13].